Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (Avutometinib Capsules; Defactinib Tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers

Key Takeaways

• Two‑year follow‑up shows median duration of response 31.1 months overall
• 52% KRAS‑mutated and 30% KRAS‑wild‑type patients stayed on therapy >1 year
• Safety remains manageable; 12% discontinued due to adverse events
• Exposure‑response analysis confirms optimal effect at approved doses
• FDA accelerated approval depends on confirmatory Phase 3 trial outcomes

Pulse Analysis

Low‑grade serous ovarian cancer (LGSOC) accounts for a small but clinically challenging subset of ovarian malignancies, affecting roughly 6,000‑8,000 women in the United States. Unlike high‑grade disease, LGSOC is less responsive to conventional chemotherapy and often harbors activating RAS pathway mutations, creating a clear rationale for targeted MAPK inhibition. Verastem’s AVMAPKI® (avutometinib) and FAKZYNJA® (defactinib) pair a MEK inhibitor with a focal adhesion kinase blocker, delivering a dual‑hit strategy designed to suppress both primary oncogenic signaling and adaptive resistance mechanisms.

The two‑year median follow‑up from the RAMP 201 Phase 2 trial provides compelling evidence that this strategy translates into lasting clinical benefit. Across 109 patients, the median duration of response remained at 31.1 months, while median progression‑free survival held steady at 12.9 months. Notably, KRAS‑mutated participants experienced a median PFS of 19.6 months, underscoring the importance of molecular selection. Safety data were consistent with earlier reports; adverse events such as skin toxicity and liver‑function test elevations were manageable, and only 12% of patients discontinued therapy because of toxicity.

These findings have significant market implications. The combination secured accelerated FDA approval in May 2025 for KRAS‑mutated recurrent LGSOC, but continued approval hinges on confirmatory Phase 3 data from the ongoing RAMP 301 trial. Success would position Verastem as a leader in a niche yet underserved oncology segment, potentially expanding the regimen into other RAS‑driven cancers like pancreatic adenocarcinoma. Competitors are pursuing MEK‑only or FAK‑only approaches, but the demonstrated durability and tolerability of the co‑pack may set a new standard of care for patients seeking long‑term disease control.